Viveon Health Acquisition Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VHAQ research report →
Price Chart
About the company
Viveon Health Acquisition Corp. presently lacks substantial ongoing operations. The company's main goal is to finalize a strategic transaction, which could include a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or a similar business combination, involving one or more companies in the North American healthcare industry.
- CEO
- Jagi Gill
- IPO
- 2021
- HQ
- Norcross, GA, US
Get TickerSpark's AI analysis on VHAQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $66.49M
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -5.95
- Div Yield
- 0.00%
- Gross Margin
- -54.85%
- Op Margin
- -94.91%
- Net Margin
- -114.57%
- ROE
- 38.48%
- ROIC
- -86.63%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-756,386+28.0%
- Op Income
- $-2,371,301
- Net Income
- $-486,788-119.6%
- EPS
- $-0.04-139.8%
- OCF Growth
- +15.8%
- FCF Growth
- +15.8%
- 52W High
- $11.90
- 52W Low
- $0.00
- 50D MA
- $10.00
- 200D MA
- $10.00
- Beta
- -0.11
- RSI (14)
- 84
- Avg Volume
- 0
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Superconductor Technologies reported another small revenue quarter, continued progress on Conductus wire, but said cash only funds operations into Q1 2020 and strategic alternatives remain under review.· November 12, 2019
- Q3 revenue was $157,000, down from $517,000 a year ago, and came entirely from the DOE NGEM project.
- Net loss was $2.4 million, or $0.43 per share, versus a $2.2 million loss, or $0.88 per share, in Q3 2018.
- Management said it has begun initial deliveries of Conductus high-performance magnet wire, but still cannot fully meet current customer commitments.
- The company said it is exploring strategic alternatives, including financing, a merger, or a sale, and is in discussions with multiple parties.
- Cash was $275,000 at quarter-end, plus about $3 million gross proceeds from an October 10 public offering; management said existing cash only lasts into the first quarter of 2020.
Third-quarter 2019 net revenue was $157,000 versus $517,000 in the third quarter of 2018, with both periods tied to work on the DOE NGEM project. R&D expense was $622,000, down from $665,000 year over year, and SG&A was $966,000 versus $1,041,000. Net loss was $2.4 million, or $0.43 per share, compared with a net loss of $2.2 million, or $0.88 per share, in Q3 2018. Cash and cash equivalents were $275,000 at September 28, and the company raised approximately $3 million gross in a public offering on October 10. Management said current cash resources are sufficient only into the first quarter of 2020.
Jeff Quiram said customer interest in high-performance superconducting magnet wire is “never been stronger,” pointing to interest from multiple well-funded fusion developers as well as the ITER project. He emphasized that the company’s focus remains on moving Conductus wire from R&D into production, while acknowledging “there’s still work to be done.” He also framed the strategic review as a response to capital needs, saying alternatives include strategic investment financing, a merger, or a sale.
Bill Buchanan highlighted that third-quarter revenue was $157,000, R&D was $622,000, SG&A was $966,000, and the quarterly net loss was $2.4 million, or $0.43 per share. He said $2.1 million was used to fund operations during the quarter and $100,000 went to working capital. He also stated that, based on current forecasts, existing cash and cash equivalents would only fund operations into the first quarter of 2020, even after the roughly $3 million gross proceeds from the October 10 offering.
There was no Q&A section on the call; management provided only prepared remarks because of the ongoing strategic initiatives review. The main issues addressed were commercialization progress, cash constraints, and the need for flexibility through a proposed reverse stock split to help address Nasdaq’s minimum bid price requirement. Management said it would not provide updates on strategic discussions unless and until further disclosure is appropriate or necessary.
The positive case from the call is that management said customer interest in Conductus-style superconducting wire is very strong, especially in fusion-related applications, and that the company has begun initial deliveries. Management also said it made progress on manufacturing readiness, with the temperature control system operational, longer wire runs underway, and third-party experts reportedly ready for long-length electroplating scale-up.
The main risk is severe liquidity pressure: cash was only $275,000 at quarter-end and management said cash lasts only into the first quarter of 2020. The company also said it is still challenged to meet current customer commitments and is not yet ready to transition to full production, while strategic alternatives remain unresolved and uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 9.8%
- Shares Outstanding
- 6.65M
- Float Shares
- 651.93K
of shares held by institutions
1 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Omni Partners Us LLC | 73.56K | ▼ 1.53K |
| Omni Partners Llp | 67.22K | ▲ 67.22K |
| Seaport Global Asset Management LLC | 700 | ▼ 1.50K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 21 | Logothetis Demetrios G. | other | 27,000 |
| Jun 1, 21 | Viveon Health, LLC | other | 27,000 |
| Apr 30, 21 | Logothetis Demetrios G. | other | 0 |
| Dec 30, 20 | Viveon Health, LLC | other | 0 |
| Dec 30, 20 | Papadopoulos Romilos | other | 0 |
| Dec 30, 20 | Gill Jagi | other | 0 |
| Dec 30, 20 | Papadopoulos Romilos | other | 656,250 |
| Dec 28, 20 | Papadopoulos Romilos | buy | 18,000,000 |
| Dec 23, 20 | Papadopoulos Romilos | other | 81,000 |
| Dec 22, 20 | Papadopoulos Romilos | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VHAQ coverage
Recent articles, reports, and earnings notes.
No research on VHAQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VHAQ report →VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS
globenewswire.com · Feb 27
VIVEON HEALTHCARE ACQUISITION CORP CONFIRMS BUSINESS COMBINATION
globenewswire.com · Feb 1
Viveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSE
globenewswire.com · Dec 27
VIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATION
globenewswire.com · Sep 15
Viveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger Agreement
globenewswire.com · Aug 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.